A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00069849

Enrollment

Registered

2003-10-02

Start date

2003-07-31

Completion date

Unknown

Last updated

2006-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.

Interventions

DRUGABT-089

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Current diagnosis of probable Alzheimer's disease. * ADAS-cog score of at least 12 and MMSE score of 10 to 26. * Non-smoker * Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person. * Fluent in English.

Exclusion criteria

* Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks. * Has clinically significant or uncontrolled medical condition other than Alzheimer's disease. * Nursing home resident.

Design outcomes

Primary

Measure	Time frame
MMSE	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026